Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer.

Shiotani A, Murao T, Kimura Y, Matsumoto H, Kamada T, Kusunoki H, Inoue K, Uedo N, Iishi H, Haruma K.

Br J Cancer. 2013 Oct 29;109(9):2323-30. doi: 10.1038/bjc.2013.596. Epub 2013 Oct 8.

2.

H. pylori eradication did not improve dysregulation of specific oncogenic miRNAs in intestinal metaplastic glands.

Shiotani A, Uedo N, Iishi H, Murao T, Kanzaki T, Kimura Y, Kamada T, Kusunoki H, Inoue K, Haruma K.

J Gastroenterol. 2012 Sep;47(9):988-98. doi: 10.1007/s00535-012-0562-7. Epub 2012 Mar 1.

PMID:
22382634
3.

Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.

Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV.

J Gastroenterol Hepatol. 2008 Nov;23(11):1666-71. Epub 2007 Jun 7.

PMID:
17559360
4.

Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori.

Haneda M, Kato M, Ishigaki S, Suzuki M, Takahashi M, Nakagawa M, Ono S, Mori Y, Mabe K, Nakagawa S, Kudo T, Shimizu Y, Asaka M.

J Gastroenterol Hepatol. 2013 Jan;28(1):78-83. doi: 10.1111/j.1440-1746.2012.07285.x.

PMID:
23034090
5.
6.

Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.

Kaise M, Miwa J, Fujimoto A, Tashiro J, Tagami D, Sano H, Ohmoto Y.

Gastric Cancer. 2013 Jul;16(3):329-37. doi: 10.1007/s10120-012-0185-y. Epub 2012 Aug 21.

PMID:
22907485
7.

Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.

Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T.

Hepatogastroenterology. 2004 Sep-Oct;51(59):1249-54.

PMID:
15362725
8.

Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.

Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, Hanaoka T, Tsugane S; Japan Public Health Center Study Group.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1341-7.

9.

Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.

Bölükbaş C, Bölükbaş FF, Ovünç O, Kiliç G, Dalay R, Güven H, Uras F, Yardimci TK, Sökmen MH, Agan AF, Pişkinpaşa N.

Turk J Gastroenterol. 2006 Sep;17(3):172-6.

10.

Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community.

Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, Xing X, Wang J, Du Z, Misumi J, Tian Q, Wang L.

Int J Cancer. 2012 Apr 1;130(7):1614-9. doi: 10.1002/ijc.26172. Epub 2011 Aug 2.

11.

Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais.

Yamada S, Matsuhisa T, Makonkawkeyoon L, Chaidatch S, Kato S, Matsukura N.

J Gastroenterol. 2006 Dec;41(12):1169-77. Epub 2007 Feb 6.

PMID:
17287896
12.

Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China.

Sun LP, Gong YH, Wang L, Yuan Y.

World J Gastroenterol. 2007 Dec 28;13(48):6562-7.

13.

Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication.

Iijima K, Koike T, Abe Y, Ara N, Uno K, Imatani A, Ohara S, Shimosegawa T.

J Gastroenterol. 2009;44(8):819-25. doi: 10.1007/s00535-009-0066-2. Epub 2009 May 14.

PMID:
19440811
14.

Serum pepsinogen II is a better diagnostic marker in gastric cancer.

Cao XY, Jia ZF, Jin MS, Cao DH, Kong F, Suo J, Jiang J.

World J Gastroenterol. 2012 Dec 28;18(48):7357-61. doi: 10.3748/wjg.v18.i48.7357.

15.

Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.

Leja M, Lapina S, Polaka I, Rudzite D, Vilkoite I, Daugule I, Belkovets A, Pimanov S, Makarenko J, Tolmanis I, Lejnieks A, Boka V, Rumba-Rozenfelde I, Vikmanis U.

Medicina (Kaunas). 2014;50(1):8-13. doi: 10.1016/j.medici.2014.05.001. Epub 2014 Jun 5.

16.

[Basal concentrations of gastrin and pepsinogen I and II in gastric ulcer: influence of Helicobacter pylori infection and usefulness in the control of the eradication].

Bermejo F, Boixeda D, Gisbert JP, Sanz JM, Defarges V, Alvarez Calatayud G, Moreno L, Martín de Argila C.

Gastroenterol Hepatol. 2001 Feb;24(2):56-62. Spanish.

PMID:
11247290
17.

Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm.

Boda T, Ito M, Yoshihara M, Kitamura Y, Matsuo T, Oka S, Tanaka S, Chayama K.

Helicobacter. 2014 Feb;19(1):1-8. doi: 10.1111/hel.12101. Epub 2013 Nov 11.

PMID:
24215601
18.

Biomarkers for Helicobacter pylori infection and gastroduodenal diseases.

Shiota S, Yamaoka Y.

Biomark Med. 2014;8(9):1127-37. doi: 10.2217/bmm.14.72. Review.

19.

Histologic and serum risk markers for noncardia early gastric cancer.

Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, Tatsuta M, Graham DY.

Int J Cancer. 2005 Jun 20;115(3):463-9.

20.

Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection.

Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, Li N, Tang B, Liu KY, Xiao B.

PLoS One. 2012;7(7):e41629. doi: 10.1371/journal.pone.0041629. Epub 2012 Jul 30.

Items per page

Supplemental Content

Write to the Help Desk